Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More
Ashwani Gujral of ashwanigujral.com is of the viw that one may buy Zee Entertainment and Hindalco Industries and advises selling Glenmark Pharma.
According to Sudarshan Sukhani of s2analytics.com, one can buy ACC, IndusInd Bank and Voltas and advises selling Idea Cellular and Glenmark Pharma.
According to Mitesh Thacker of miteshthacker.com, one can sell Glenmark Pharma and buy Arvind.
Ashwani Gujral of ashwanigujral.com suggests buying UPL, Gujarat Mineral Development Corporation and Container Corporation of India and advises selling Glenmark Pharma and HDFC.
Mitesh Thacker of miteshthacker.com is of the view that one can sell Glenmark Pharma and buy Cipla, Cummins India and AIA Engineering.
Here are a few top buzzing stocks picked by CNBC-TV18's analysts in trade today -- Idea Cellular, Sun Pharma, DRL, Lupin, Aurobindo Pharma , Glenmark, Natco Pharma, Alkem Labs, Ajanta Pharma, Strides Shasun, Biocon, Cipla, Cyient, MMTC and Power Grid.
Credit Suisse stays outperform rating on L&T and Sadbhav Engineering. It has outperform rating on L&T on pick-up in domestic execution, strong earnings growth.
Nomura has a buy ratings on Dr Reddy‘s, Glenmark, Alkem, Cadila and Jubilant Life. It says Teva‘s 2017 guidanceis lower than what was presented in 2016-2020 prelim outlook and implies a shortfall of USD 1.5-2 billion in EBITDA. Teva expects mid-single digit price erosion in the base US business.
Mitesh Thacker of miteshthacker.com suggests buying Tata Motors and Glenmark Pharma.
Rajat Bose of rajatkbose.com recommends buying IL&FS Transport and Glenmark Pharma.
Mitesh Thacker of miteshthacker.com suggests buying Cummins India and NBCC and advises selling Glenmark Pharma.
Nomura is neutral on Lupin and Torrent. It has a buy rating on Dr Reddy‘s and Cadila. It says trailing three-month sales declined sequentially for Torrent, Sun Pharma and Glenmark. Torrent‘s sales were down on account of price erosion in gAbilify. Sun‘s T3M sales declined QoQ due to price erosion and market share loss in gGleevec.
Mitesh Thacker of miteshthacker.com is of the view that one can buy Bosch and sell Glenmark Pharma.
In an interview with CNBC-TV18, SP Tulsian of sptulsian.com gave his stock picks for the day and shared his market outlook.
Ashwani Gujral of ashwanigujral.com is of the view that one may sell Glenmark Pharma and Biocon and buy Hindustan Unilever.
Valuations of Glenmark look attractive, Macquarie says, adding it is one the top picks in pharma space with a target of Rs 1,350.
In an interview to CNBC-TV18 SP Tulsian of sptulsian.com shares what is a a good level to enter the Glenmark pharma stock. He also shares his view on other stocks like Laurus Labs, which listed today, defence picks like Bharat Forge, and agro companies like Jayant Agro.
Chandan Taparia, Derivative & Technical Analyst at Anand Rathi Securities is of the view that one can buy Glenmark Pharma, Cummins India, Tata Motors and Exide Industries.
Mitesh Thacker of miteshthacker.com is of the view that one can sell Federal Bank, Havells India and REC and buy Glenmark Pharma and Mahindra Holidays.
Jay Thakkar of Sharekhan is of the view that one may buy Tata Global Beverage with a target of Rs 130.50.
Ashwani Gujral of ashwanigujral.com recommends buying Glenmark Pharma and EID Parry and advises selling HDIL.
Mitesh Thacker of miteshthacker.com is of the view that one can buy Glenmark Pharma and sell Bosch.
Rajesh Kothari, Managing Director at AlfAccurate Advisors has a bullish stance on Ipca Laboratories and feels that earnings growth can be very strong over the next 2-3 years.
Amit Gupta of ICICIdirect recommends buying Hindalco Industries 190 Call and feels that Glenmark Pharma may test Rs 940.
SP Tulsian of sptulsian.com shares his rationale behind his bullish view on Crompton Greaves, Motherson Sumi and Bharat Forge.